1. Development of a transplantable glioma tumour model from genetically engineered mice: MRI/MRS/MRSI characterisation
   Magdalena Ciezka et al, 2016, J Neurooncol CrossRef
2. Mechanistic study of IR-780 dye as a potential tumor targeting and drug delivery agent
   Erlong Zhang et al, 2014, Biomaterials CrossRef
3. Salinomycin inhibits the tumor growth of glioma stem cells by selectively suppressing glioma-initiating cells
   TUNAN CHEN et al, 2015 CrossRef
4. Adipocyte proteome and secretome influence inflammatory and hormone pathways in glioma
   J. Almeida et al, 2018, Metab Brain Dis CrossRef
5. Endogenous Brain Pericytes Are Widely Activated and Contribute to Mouse Glioma Microvasculature
   Andreas Svensson et al, 2015, PLoS ONE CrossRef
6. Glioma Stem Cells but Not Bulk Glioma Cells Upregulate IL-6 Secretion in Microglia/Brain Macrophages via Toll-like Receptor 4 Signaling
   Omar Dildar a Dzaye et al, 2016, J Neuropathol Exp Neurol CrossRef
7. Development of a Mouse Glioblastoma Orthotopic Model Using the GLi-261 Cell Line
   A. A. Borzov et al, 2019, Biopreparaty. Profilaktika, diagnostika, lechenie CrossRef
8. Connexin43 peptide, TAT-Cx43266–283, selectively targets glioma cells, impairs malignant growth, and enhances survival in mouse models in vivo
   Myriam Jaraíz-Rodríguez et al, 2019 CrossRef
9. null
   N. Mendes et al, 2020 CrossRef
10. Lucanthone Targets Lysosomes to Perturb Glioma Proliferation, Chemoresistance and Stemness, and Slows Tumor Growth In Vivo
    Daniel P. Radin et al, 2022, Front. Oncol. CrossRef
11. Thioredoxin Reductase Inhibitors as Potential Antitumors: Mercury Compounds Efficacy in Glioma Cells
    Vanessa Pires et al, 2022, Front. Mol. Biosci. CrossRef
12. Antigen presentation deficiency, mesenchymal differentiation, and resistance to immunotherapy in the murine syngeneic CT2A tumor model
    J. Bryan Iorgulescu et al, 2023, Front. Immunol. CrossRef
13. Understanding current experimental models of glioblastoma-brain microenvironment interactions
    Niket Yadav et al, 2024, J Neurooncol CrossRef
14. Lucanthone, a Potential PPT1 Inhibitor, Perturbs Stemness, Reduces Tumor Microtube Formation, and Slows the Growth of Temozolomide-Resistant Gliomas In Vivo
    Daniel P. Radin et al, 2024, The Journal of Pharmacology and Experimental Therapeutics CrossRef